SELLAS Life Sciences (SLS) Research & Development (2010 - 2026)
SELLAS Life Sciences (SLS) reported Research & Development of $5.1 million for Q1 2026, up 60.03% year-over-year from $3.2 million in Q1 2025, and up 8.44% quarter-over-quarter from $4.7 million in Q4 2025.
SELLAS Life Sciences (SLS) Research & Development (2010 - 2026) Analysis & Trends
SELLAS Life Sciences (SLS) has 17 years of Research & Development data on file, last reported at $5.1 million in Q1 2026.
- Research & Development for Q1 2026 came in at $5.1 million, up 60.03% year-over-year; the trailing twelve-month figure through Mar 2026 was $17.9 million (up 4.4% YoY), and the FY2025 annual result was $16.0 million, down 16.1% from the prior year.
- Research & Development rose to $5.1 million in Q1 2026 per SLS's latest filing, from $4.7 million in the prior quarter.
- Over five years, Research & Development peaked at $7.2 million in Q1 2023 and troughed at $3.2 million in Q1 2025.
- A 5-year average of $5.0 million and a median of $5.1 million in 2023 frame the typical range for Research & Development.
- The sharpest annual moves came in 2022 and 2025: Research & Development surged 72.3% in 2022, then slumped 37.29% in 2025.
- A 5-year view of Research & Development shows it stood at $5.8 million in 2022, then slipped by 12.81% to $5.1 million in 2023, then declined by 12.95% to $4.4 million in 2024, then increased by 6.6% to $4.7 million in 2025, then rose by 8.44% to $5.1 million in 2026.
- Business Quant data shows SLS's Research & Development at $5.1 million in Q1 2026, $4.7 million in Q4 2025, and $4.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 4.32 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 15.66 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 626,092.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -101.30 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -2.30 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 1.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 357,444.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 961.60 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -58.00 Mn |
| 10 | SELLAS Life Sciences | 1.39 Bn | 1.39 Bn | - | 5.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.13 Mn |
| Dec 31, 2025 | 4.73 Mn |
| Sep 30, 2025 | 4.22 Mn |
| Jun 30, 2025 | 3.87 Mn |
| Mar 31, 2025 | 3.21 Mn |
| Dec 31, 2024 | 4.44 Mn |
| Sep 30, 2024 | 4.36 Mn |
| Jun 30, 2024 | 5.19 Mn |
| Mar 31, 2024 | 5.11 Mn |
| Dec 31, 2023 | 5.10 Mn |
| Sep 30, 2023 | 5.81 Mn |
| Jun 30, 2023 | 5.92 Mn |
| Mar 31, 2023 | 7.17 Mn |
| Dec 31, 2022 | 5.85 Mn |
| Sep 30, 2022 | 4.28 Mn |
| Jun 30, 2022 | 5.53 Mn |
| Mar 31, 2022 | 4.61 Mn |
| Dec 31, 2021 | 3.39 Mn |
| Sep 30, 2021 | 4.54 Mn |
| Jun 30, 2021 | 3.46 Mn |